Objectives: To perform a large-scale investigation of Pseudomonas aeruginosa strains with and without drug resistance in Japan.
Introduction
Pseudomonas aeruginosa has intrinsic resistance to many antimicrobial agents, and only a few antimicrobial agents show potent antibacterial activity against this bacterium. The emergence of multidrug-resistant (MDR) P. aeruginosa strains is a serious problem. 1 -3 Nosocomial outbreaks of P. aeruginosa infection, particularly by MDR strains, have become problematic in hospitals in various countries, 4 -8 including in Japan. 3, 9, 10 Many cases of MDR P. aeruginosa infection have been reported in Japan. However, there have been few nationwide investigations of the prevalence P. aeruginosa infection at medical facilities. We investigated isolation rates of P. aeruginosa strains with and without drug resistance in cooperation with various medical facilities and clinical laboratories throughout Japan. This is the first surveillance study of clinically isolated P. aeruginosa with and without drug resistance in Japan.
Materials and methods

Methods and subjects
Information was gathered by means of a questionnaire. 
Questionnaires
The questionnaire enquired about (i) the number of beds, (ii) the total number of P. aeruginosa strains isolated each year with or without TDR or MDR, (iii) the number of patients with TDR or MDR strains and (iv) the tissue sources of the isolated strains.
Clinical isolation of P. aeruginosa strains P. aeruginosa strains were isolated from inpatients and outpatients with suspected P. aeruginosa infection and subjected to drugsusceptibility testing. Repeat testing of single patients was assumed when repeat examinations were ordered. Strains isolated for analysis in this study were not from the environment, carriers, nonsymptomatic patients or healthy staff.
Drug-resistant strains
Strains that were resistant to carbapenems, fluoroquinolones (ciprofloxacin or levofloxacin) and amikacin were defined as MDR strains. Strains that were resistant to two of these drugs were defined as two-drug-resistant (TDR) strains. Drug resistance was assessed by determining the MIC in culture medium containing the drugs or by determining the diameter of the growth inhibition zone (DGIZ) on culture agar with the use of drug-containing discs. Breakpoints were determined in accordance with the criteria for MDR strains specified by the Law Concerning the Prevention of Infections and Medical Care for Patients with Infections of the Japanese Ministry of Health, Labour and Welfare. MIC breakpoints for carbapenems, amikacin, ciprofloxacin and levofloxacin were 16, 32, 4 and 8 mg/L, respectively; DGIZ breakpoints for these drugs were 13, 14, 15 and 13 mm, respectively.
Drug susceptibility tests for bacteria, including P. aeruginosa, are performed in Japan in accordance with the standards published by the Clinical and Laboratory Standards Institute, Wayne, PA, USA.
Statistical analysis
Chronological trends in the proportions of TDR and MDR isolates were assessed by the Mantel -Haenszel x 2 test. The numbers of isolates from various tissue sources were analysed by the x 2 test. P values of ,0.0001 were considered statistically significant.
Results
P. aeruginosa isolates and infections at medical facilities
During the study period, a total of 549 746 P. aeruginosa strains were isolated at the 339 medical facilities. The numbers of TDR and MDR isolates were 35 030 (6.4%) and 13 296 (2.4%), respectively. As shown in the upper half of Table 1, the Forty-eight facilities (14.2%) reported isolation of no MDR P. aeruginosa strains during the study period. The number of patients with MDR per 1000 beds per month was less than two in 90.4%, 89.0%, 87.9% and 89.3% of the facilities in 2003 -06, respectively, whereas two or more patients with MDR strains were identified in 10% of the facilities during the study period, suggesting that MDR P. aeruginosa was prevalent in a limited number of hospitals. We then investigated whether high incidence of MDR occurred geographically. No significant difference between geographic areas was found (data not shown).
P. aeruginosa isolated at clinical laboratories
Completed questionnaires from the four clinical laboratories were also analysed. The number of P. aeruginosa strains isolated during the study period was 640 232, and the numbers of TDR and MDR isolates were 26 913 (4.2%) and 6768 (1.1%), respectively. The data for each year are shown in the lower half of Table 1 . The numbers increased markedly from 2003 to 2005, but the percentages of TDR and MDR did not. It could not be determined whether the percentages increased in 2006, given that data were obtained for only half of the year.
Comparison of the percentages of TDR and MDR isolates from the laboratories with those from the medical facilities showed lower percentages from the laboratories.
Tissue sources of P. aeruginosa
The tissue sources and percentages of the total P. aeruginosa strains isolated at the 339 medical facilities for the study periods and those of TDR and MDR strains are shown in Figure 1a . The percentages for each year were similar to those for the entire study period (data not shown). These results indicated that P. aeruginosa, including TDR and MDR strains, affected mainly the respiratory and urinary tracts. However, it is notable that the percentages of TDR and MDR isolates in the urinary tract were significantly greater than that of the total isolates (P , 0.0001) and the percentages of MDR The ratio of the numbers of TDR or MDR P. aeruginosa to the total numbers of isolated P. aeruginosa (%). c The numbers of patients with TDR or MDR P. aeruginosa. Figure 1 . Tissue sources of total P. aeruginosa strains, TDR strains and MDR strains isolated during the study period at medical facilities (a) and clinical laboratories (b). An asterisk indicates a significant difference between numbers of TDR and total isolates or between MDR and total isolates. TDR, two-drug-resistant; MDR, multidrug-resistant.
isolates in the urinary tract surpassed those in the respiratory tract.
The tissue sources and percentages of P. aeruginosa isolated at the four clinical laboratories during the study period were also analysed (Figure 1b) . The results showed that the percentage of MDR isolates in the urinary tract was significantly greater than that of the total and TDR strains (P , 0.0001).
Discussion
It was not practical to send questionnaires to all medical facilities and laboratories in Japan. Therefore, we selected all large-scale facilities and many regional core hospitals, as well as highly respected laboratories, by considering their geographic locations across the country. Data collected by these laboratories may provide information for various clinics and small-scale hospitals, and may shed light on different aspects of P. aeruginosa prevalence. By analysing questionnaires completed by 339 medical facilities and 4 laboratories, we believe that we obtained accurate information regarding the present state of P. aeruginosa prevalence in Japan. However, the use of retrospective data implies inherent biases.
Our survey showed that MDR P. aeruginosa was prevalent nationwide but the incidence was low, except in a limited number of facilities. The survey also showed that MDR strains were isolated from the urinary tract as well as the respiratory tract, suggesting the importance of management of patient's urine in the prevention and control of nosocomial MDR P. aeruginosa infection. 3, 9 The samples from clinical laboratories may provide information on the prevalence of P. aeruginosa infection at clinics and small-scale hospitals. The percentages of TDR and MDR P. aeruginosa isolates from the laboratories were lower than those from the medical facilities. Although the exact reasons are unclear, this may be related to differences in the use of antibiotics, the severity of cases, scales of nosocomial outbreaks and populations of inpatients and outpatients.
